Evidence map›Paper›PMID 29500820›Full record

ArticleBritish journal of pharmacology2018

Activity of novel lipid glycine transporter inhibitors on synaptic signalling in the dorsal horn of the spinal cord.

Bryony L Winters, Tristan Rawling, Robert J Vandenberg, Macdonald J Christie, Rebecca F Bhola, Wendy L Imlach

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Opiranserin (VVZ-149): what's new in analgesics.The Korean journal of pain · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Bryony L WintersPain Management Research Institute, Kolling Institute of Medical Research, The University of Sydney, Royal North Shore Hospital, St Leonards, NSW, Australia.
Tristan RawlingSchool of Mathematical and Physical Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, Australia.
Robert J VandenbergDiscipline of Pharmacology, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Macdonald J ChristieDiscipline of Pharmacology, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Rebecca F BholaDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.
Wendy L ImlachDepartment of Physiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.ORCID 0000-0002-7521-9969
Discovery Institute · USThe University of Sydney · AURoyal North Shore Hospital · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeInhibitory neurotransmission plays an important role in controlling excitability within nociceptive circuits of the spinal cord dorsal horn. Loss of inhibitory signalling is thought to contribute to the development of pathological pain. Preclinical studies suggest that increasing inhibitory glycinergic signalling is a good therapeutic strategy for treating pain. One approach to increase synaptic glycine is to inhibit the activity of the glycine transporter 2 (GlyT2) on inhibitory nerve terminals. These transporters are involved in regulating glycine concentrations and recycling glycine into presynaptic terminals. Inhibiting activity of GlyT2 increases synaptic glycine, which decreases excitability in nociceptive circuits and provides analgesia in neuropathic and inflammatory pain models. EXPERIMENTAL APPROACH: We investigated the effects of reversible and irreversible GlyT2 inhibitors on inhibitory glycinergic and NMDA receptor-mediated excitatory neurotransmission in the rat dorsal horn. The effect of these drugs on synaptic signalling was determined using patch-clamp electrophysiology techniques to measure glycine- and NMDA-mediated postsynaptic currents in spinal cord slices in vitro. KEY

resultsWe compared activity of four compounds that increase glycinergic tone with a corresponding increase in evoked glycinergic postsynaptic currents. These compounds did not deplete synaptic glycine release over time. Interestingly, none of these compounds increased glycine-mediated excitatory signalling through NMDA receptors. The results suggest that these compounds preferentially inhibit GlyT2 over G1yT1 with no potentiation of the glycine receptor and without inducing spillover from inhibitory to excitatory synapses. CONCLUSIONS AND IMPLICATIONS: GlyT2 inhibitors increase inhibitory neurotransmission in the dorsal horn and have potential as pain therapeutics. LINKED ARTICLES: This article is part of a themed section on Recent Advances in Targeting Ion Channels to Treat Chronic Pain. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc.

Indexed as

AnimalsGlycine AgentsGlycine Plasma Membrane Transport ProteinsMaleMolecular StructureRatsRats, Sprague-DawleySpinal CordSpinal Cord Dorsal HornSynapsesSynaptic TransmissionGlycine AgentsGlycine Plasma Membrane Transport ProteinsSlc6a5 protein, rat

Identifiers

PMID29500820
PMCPMC5980266
OpenAlexW2793385789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.